These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 29773827

  • 1. Cardiac pacemaker channel (HCN4) inhibition and atrial arrhythmogenesis after releasing cardiac sympathetic activation.
    Chobanyan-Jürgens K, Heusser K, Duncker D, Veltmann C, May M, Mehling H, Luft FC, Schröder C, Jordan J, Tank J.
    Sci Rep; 2018 May 17; 8(1):7748. PubMed ID: 29773827
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Ivabradine augments high-frequency dynamic gain of the heart rate response to low- and moderate-intensity vagal nerve stimulation under β-blockade.
    Kawada T, Yamamoto H, Uemura K, Hayama Y, Nishikawa T, Zheng C, Li M, Miyamoto T, Sugimachi M.
    Am J Physiol Heart Circ Physiol; 2021 Jun 01; 320(6):H2201-H2210. PubMed ID: 33891515
    [Abstract] [Full Text] [Related]

  • 8. Analysis of variants in the HCN4 gene and in three single nucleotide polymorphisms of the CYP3A4 gene for association with ivabradine reduction in heart rate: A preliminary report.
    Núñez L, Crespo-Leiro MG, Marrón-Liñares GM, Suarez-Fuentetaja N, Barge-Caballero E, Paniagua-Martín MJ, Marzoa-Rivas R, Grille-Cancela Z, Muñiz-García J, Vazquez-Rodriguez JM, Hermida-Prieto M.
    Cardiol J; 2016 Jun 01; 23(5):573-582. PubMed ID: 27439367
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Properties of ivabradine-induced block of HCN1 and HCN4 pacemaker channels.
    Bucchi A, Tognati A, Milanesi R, Baruscotti M, DiFrancesco D.
    J Physiol; 2006 Apr 15; 572(Pt 2):335-46. PubMed ID: 16484306
    [Abstract] [Full Text] [Related]

  • 13. Selective pharmacological inhibition of the pacemaker channel isoforms (HCN1-4) as new possible therapeutical targets.
    Koncz I, Szél T, Jaeger K, Baczkó I, Cerbai E, Romanelli MN, Gy Papp J, Varró A.
    Curr Med Chem; 2011 Apr 15; 18(24):3662-74. PubMed ID: 21774761
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. PP2 prevents isoproterenol stimulation of cardiac pacemaker activity.
    Huang J, Lin YC, Hileman S, Martin KH, Hull R, Yu HG.
    J Cardiovasc Pharmacol; 2015 Feb 15; 65(2):193-202. PubMed ID: 25658311
    [Abstract] [Full Text] [Related]

  • 16. Specific inhibition of HCN channels slows rhythm differently in atria, ventricle and outflow tract and stabilizes conduction in the anoxic-reoxygenated embryonic heart model.
    Sarre A, Pedretti S, Gardier S, Raddatz E.
    Pharmacol Res; 2010 Jan 15; 61(1):85-91. PubMed ID: 19818405
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Ivabradine for the Treatment of Cardiovascular Diseases.
    Ide T, Ohtani K, Higo T, Tanaka M, Kawasaki Y, Tsutsui H.
    Circ J; 2019 Jan 25; 83(2):252-260. PubMed ID: 30606942
    [Abstract] [Full Text] [Related]

  • 20. Updates on HCN Channels in the Heart: Function, Dysfunction and Pharmacology.
    Sartiani L, Romanelli MN, Mugelli A, Cerbai E.
    Curr Drug Targets; 2015 Jan 25; 16(8):868-76. PubMed ID: 26028050
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.